MKI67 and pancreatic neuroendocrine tumor: In the CLARINET study, lanreotide was associated with significantly prolonged PFS among patients with metastatic enteropancreatic NETs G1-2, with Ki-67 <10%.53 When advanced pancreatic NETs were analyzed, for asymptomatic patients with low tumor burden and disease progression under SSAs, everolimus or sunitinib were the preferred second-line treatment options.40,54 Given this scenario, achieving an objective response does not appear to be a treatment goal priority.